The Harry Kazmi Foundation is proud to announce that it has become a member of the American Society of Clinical Oncology (ASCO), one of the world’s leading organisations dedicated to advancing cancer research, clinical practice and patient care.
ASCO is recognised globally as a leading authority in oncology, bringing together more than 50,000 oncologists, researchers, healthcare professionals and patient advocates from over 150 countries. Its membership represents an international community committed to accelerating scientific discovery, improving patient outcomes and shaping the future of cancer care.
Membership of ASCO is a significant milestone, reflecting the Foundation’s commitment to engaging with the international oncology community. Admission is subject to ASCO’s eligibility requirements, placing the Foundation within one of the world’s most respected professional networks in cancer research.
Strengthening International Collaboration
ASCO provides the Harry Kazmi Foundation with the opportunity to engage more closely with the global oncology community, strengthening relationships with clinicians, researchers, academic institutions, healthcare organisations and industry partners working at the forefront of cancer research.
As a member, the Foundation will benefit from access to:
- The latest oncology research and scientific developments.
- Leading educational resources and professional publications.
- International conferences and specialist educational programmes.
- Opportunities to connect with world-leading cancer researchers and healthcare professionals.
- A global network dedicated to improving cancer prevention, diagnosis, treatment and survivorship.
- Opportunities to develop strategic partnerships that support research, innovation and knowledge sharing.
These resources will help ensure the Foundation remains informed about emerging scientific advances and evolving standards of care, particularly in areas relevant to rare and childhood cancers.
Advancing Research Through Global Collaboration
Breakthroughs in cancer research are driven by international collaboration, the exchange of scientific knowledge and strong partnerships across the oncology community. As an ASCO member, the Harry Kazmi Foundation will be better connected to leading clinicians, researchers, academic institutions and healthcare organisations committed to advancing cancer research.
Membership provides valuable opportunities to stay informed about emerging scientific discoveries, advances in precision oncology, genomics, immunotherapy and clinical trials, while also fostering relationships that can support future collaborative research initiatives and strategic partnerships.
By strengthening these global connections, the Foundation will be better positioned to contribute to the advancement of research into rare cancers, encourage knowledge sharing and support initiatives that have the potential to improve outcomes for patients and their families worldwide.
Accelerating Progress in Alveolar Rhabdomyosarcoma
A central focus of The Harry Kazmi Foundation is to support progress in alveolar rhabdomyosarcoma, one of the rarest and most aggressive cancers affecting children, teenagers and young adults. Because relatively few patients are diagnosed each year, meaningful progress relies on international collaboration, shared scientific expertise and access to the latest research.
Through its ASCO membership, the Foundation will be better positioned to engage with the global sarcoma and paediatric oncology community, helping to build relationships with leading experts, research institutions and organisations dedicated to improving outcomes for patients with rare cancers.
By remaining connected to the latest advances in molecular profiling, precision medicine, genomics, immunotherapy and emerging treatment approaches, the Foundation aims to help foster collaboration that supports faster research, greater awareness and increased opportunities for innovation. These connections will strengthen the Foundation’s ability to champion research that has the potential to improve survival and quality of life for people diagnosed with alveolar rhabdomyosarcoma.
A Commitment to Excellence
Joining ASCO reflects the Foundation’s commitment to ensuring that its work is informed by the highest standards of scientific evidence, international collaboration and clinical excellence. It demonstrates a commitment to engaging with the world’s leading oncology community and supporting initiatives that advance research, education and innovation.
As cancer research continues to evolve at an unprecedented pace, The Harry Kazmi Foundation remains committed to working alongside clinicians, researchers, charities and industry partners around the world to accelerate research into alveolar rhabdomyosarcoma and other rare cancers, helping to create a future where every patient has access to better treatments, greater hope and improved outcomes.